Anti-Clec12A Antibodies for ADCC-Driven Leukemia Cell Killing
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for autoimmune diseases and certain cancers, such as leukemia, lymphoma, and myeloma, lack effective therapies that target the Clec12A antigen, which is expressed on myeloid cells and plays a role in immune response and inflammation.
Innovation Solution
Development of human anti-Clec12A antibodies and fragments thereof, which can induce apoptosis and inhibit cancer cell proliferation through Antibody-dependent cellular cytotoxicity (ADCC) activity, and can be used alone or in combination with other treatment modalities.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If current treatments are used for autoimmune diseases and cancers, then existing therapy options are available, but effective therapies targeting Clec12A antigen are lacking
Solution Approach 1:
The patent segments the immune system targeting approach by specifically targeting Clec12A antigen on myeloid cells, separating this target from other immune checkpoints. This segmentation enables specialized therapy for diseases driven by Clec12A-mediated immune suppression without affecting other immune pathways.
Solution Approach 2:
The patent introduces anti-Clec12A antibodies as intermediary molecules that bind to Clec12A antigen and recruit immune cells through ADCC mechanism. These antibodies serve as mediators between the therapeutic agent and the target antigen, enabling indirect elimination of cancer cells and modulation of autoimmune responses.
2Reliability
If Clec12A antigen is targeted for therapeutic effect, then cancer cell proliferation is inhibited and apoptosis is induced, but the mechanism requires Antibody-dependent cellular cytotoxicity activity
Solution Approach 1:
The anti-Clec12A antibody therapy utilizes the body's own immune system cells (NK cells, macrophages, etc.) to execute the cytotoxic function through ADCC. The antibody serves as a guide, while the immune cells provide the killing mechanism, eliminating the need for direct cytotoxic moieties on the antibody and simplifying the overall therapeutic mechanism.
3Adaptability or versatility
If Clec12A is expressed on myeloid cells including granulocytes, monocytes, macrophages and dendritic cells, then immune response modulation occurs, but the antigen's inhibitory function on granulocyte and monocyte function must be overcome
Solution Approach 1:
The patent converts the harmful immune suppression function of Clec12A into a beneficial target for therapy. By targeting Clec12A with antibodies, the therapy exploits the antigen's presence on myeloid cells to redirect immune responses against cancer cells, transforming the antigen's natural immunosuppressive role into an opportunity for immune activation against malignancies.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The anti-Clec12A antibodies demonstrate strong binding affinity and efficacy in treating autoimmune diseases and cancers by inducing apoptosis and inhibiting cancer cell proliferation, offering a novel therapeutic approach.
Implementation Method 1
Binding of human Clec12A with the anti-Clec12A antibodies or fragments thereof described herein may demonstrate Antibody-dependent cellular cytotoxicity (ADCC) activity
Implementation Method 2
induction of apoptosis and inhibition of cancer cell proliferation
Implementation Method 3
induction of apoptosis and inhibition of cancer cell proliferation
Data Source
AI summary
Antibodies, fragments thereof and fusion proteins that specifically bind to Clec12A, are described, as well as methods of making and using such antibodies. Such antibodies, fusion proteins and fragments thereof are useful for the treatment and diagnosis of various autoimmune diseases and cancers, including leukemia, lymphoma, or myeloma, including, for example, acute myeloid leukemia.